Deutsche Bank AG Has $806,000 Stock Holdings in Fulcrum Therapeutics, Inc. $FULC

Deutsche Bank AG lessened its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 2.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 279,812 shares of the company’s stock after selling 5,679 shares during the period. Deutsche Bank AG owned approximately 0.52% of Fulcrum Therapeutics worth $806,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. MetLife Investment Management LLC raised its position in Fulcrum Therapeutics by 145.8% in the fourth quarter. MetLife Investment Management LLC now owns 40,107 shares of the company’s stock worth $189,000 after purchasing an additional 23,792 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in Fulcrum Therapeutics in the fourth quarter worth about $38,000. Millennium Management LLC increased its holdings in shares of Fulcrum Therapeutics by 224.0% during the fourth quarter. Millennium Management LLC now owns 76,123 shares of the company’s stock worth $358,000 after buying an additional 52,628 shares in the last quarter. Northern Trust Corp raised its stake in shares of Fulcrum Therapeutics by 25.1% in the fourth quarter. Northern Trust Corp now owns 710,321 shares of the company’s stock valued at $3,339,000 after acquiring an additional 142,578 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Fulcrum Therapeutics in the first quarter valued at approximately $144,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. HC Wainwright upgraded shares of Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the company from $4.00 to $12.00 in a research note on Tuesday, July 29th. Wall Street Zen cut shares of Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Leerink Partnrs upgraded shares of Fulcrum Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 23rd. Leerink Partners raised shares of Fulcrum Therapeutics from a “market perform” rating to an “outperform” rating and raised their price target for the company from $4.00 to $12.00 in a report on Friday, May 23rd. Finally, Piper Sandler reissued an “overweight” rating and issued a $9.00 price target (up previously from $6.00) on shares of Fulcrum Therapeutics in a report on Thursday, May 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.57.

Fulcrum Therapeutics Stock Performance

Shares of FULC opened at $6.41 on Tuesday. The firm has a market cap of $346.73 million, a P/E ratio of -5.25 and a beta of 2.47. Fulcrum Therapeutics, Inc. has a 52 week low of $2.32 and a 52 week high of $9.90. The firm’s 50-day simple moving average is $7.10 and its 200 day simple moving average is $5.30.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings results on Tuesday, July 29th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. As a group, equities analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.